About Lyell Immunopharma, Inc. 
Lyell Immunopharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 35 Schemes (10.58%)
Foreign Institutions
Held by 60 Foreign Institutions (24.33%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
No Data
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2025)
Net Profit:
-141 Million
Pharmaceuticals & Biotechnology
USD 492 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.94
-54.68%
1.50






